Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab

EpCAM is an attractive target for cancer therapy and the EpCAM-specific antibody catumaxomab has been used for intraperitoneal treatment of EpCAM-positive cancer patients with malignant ascites. New prognostic markers are necessary to select patients that mostly benefit from catumaxomab. Recent data...

Descripción completa

Detalles Bibliográficos
Autores principales: Seeber, Andreas, Braicu, Ioana, Untergasser, Gerold, Nassir, Mani, Fong, Dominic, Botta, Laura, Gastl, Guenther, Fiegl, Heidi, Zeimet, Alain, Sehouli, Jalid, Spizzo, Gilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694811/
https://www.ncbi.nlm.nih.gov/pubmed/26296970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694811/
https://www.ncbi.nlm.nih.gov/pubmed/26296970

Ejemplares similares